Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Drug-Eluting Stent Study Evaluating a New Technology in Patients with Symptomatic Ischemic Heart Disease due to Coronary Artery Blockage.

X
Trial Profile

Drug-Eluting Stent Study Evaluating a New Technology in Patients with Symptomatic Ischemic Heart Disease due to Coronary Artery Blockage.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Ischaemic heart disorders
  • Focus First in man; Therapeutic Use
  • Acronyms DIRECT; DIRECT I FIM; DIRECT-I
  • Sponsors Svelte Medical Systems
  • Most Recent Events

    • 11 Jul 2018 Status changed from active, no longer recruiting to completed.
    • 23 May 2013 Final 6 and 12-month results were presented at the 2013 EuroPCR meeting and have been published in EuroIntervention, according a Svelte Medical Systems media release.
    • 30 Jan 2013 Positive 6-month results have been reported in a Svelte Medical Systems media release. Final 6-month data will be presented at a medical symposia later in 2013.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top